Sector News

UCB to build €300M biologics plant, add 150 workers

December 26, 2019
Life sciences

UCB, which recently pulled off a $2.5 billion for an autoimmune drug candidate, says it sees the need for more biopharma production. To fill it, it will build a €300 million ($333 million) facility and staff it with 150 new workers.

The Belgium company says work on the facility will begin soon at its site in Braine l’Alleud, Wallonia, Belgium. The plant is slated to be operational in 2024.

It said the biotechnology plant is needed for the future launch of monoclonal antibody drug therapies in clinical development.

“The shift of our pipeline towards large molecules requires us to ramp up investment in mammalian technical development, as well as our manufacturing capabilities,” Kirsten Lund-Jurgensen, head of supply and technology at UCB, said in a statement.

The announcement comes just two months after UCB struck a deal to acquire Cambridge, Massachusetts biotech Ra Pharmaceuticals. With the takeover, UCB will get a phase 3 rival to Alexion’s Soliris that analysts have pegged to hit blockbuster sales.

The Ra drug candidate is focused on a once-daily, self-administered, subcutaneous C5 inhibitor called zilucoplan which is in phase 3 trials for myasthenia gravis.

MG is a long-term autoimmune neuromuscular condition that causes muscle weakness, particularly affecting the face, but can also extend to the arms legs and neck in more severe cases, known as generalized MG. It can cause difficulties with swallowing, speaking and breathing and in some cases these can become severe—known as a myasthenic crisis—and require hospitalization.

By Eric Palmer

Source: Fierce Pharma

Related News

October 24, 2020

Neutralising the gluten threat: are we on the cusp of a coeliac disease breakthrough?

Life sciences

Coeliac disease causes long-term damage to patients’ small intestine and puts them at risk of other medical conditions. Treatment options are urgently needed. Allie Nawrat explores the promise of larazotide, the drug in development currently leading the pack.

October 24, 2020

Bone Therapeutics showcases allogeneic cell therapy data

Life sciences

Bone Therapeutics has announced positive 24-month follow-up results from its phase IIa study of Allob, its allogeneic cell therapy, in patients undergoing lumbar spinal fusion procedures.

October 24, 2020

UCB acquires new campus to support UK operations

Life sciences

Belgian pharma company UCB has agreed to acquire a new campus to further support its operations in the UK.

Send this to a friend